Page 3 - Renin Angiotensin Aldosterone System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alnylam Pharma (ALNY) Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran

Alnylam Pharma (ALNY) Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomGeorgel bakrisSimon foxJosh brodskyChristine regan lindenboomHealth promotion seriesAlnylam pharmaceuticals nasdaqJournal of the american college cardiologyAlnylam pharmaceuticalsZilebesiran program lead at alnylamUniversity of chicago medicineWorld health organizationAlnylam pharmaceuticals incAmerican heart association comprehensive hypertension centerSecurities exchange

F Hoffmann-La Roche Ltd: Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

F Hoffmann-La Roche Ltd: Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergBruno eschliRebekka schnellKirti pandeyBirgit masjostLoren kalmNathalie altermattGerard tobinSabine borngrRoche groupRoche group media relationsRenin angiotensin aldosterone systemEnhanced stabilisation chemistry plusDow jones sustainability indicesChugai pharmaceutical

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - -.

United statesUnited kingdomGeorgel bakrisSimon foxJournal of the american college cardiologyExchange commissionUniversity of chicago medicineZilebesiran program lead at alnylamAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqWorld health organizationAmerican heart association comprehensive hypertension centerSecurities exchangeHealth promotion seriesAlnylam pharmaceuticals incProfessor george

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic currently in Phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent .

United statesRoche pharmaYvonne greenstreet mbchTeresa grahamWorld health organizationRoche groupB circulation researchYvonne greenstreetChief executive officerRenin angiotensin aldosterone systemEnhanced stabilization chemistry plusDow jones sustainability indicesChugai pharmaceuticalReviews diseaseWorld health

F Hoffmann-La Roche Ltd: Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

F Hoffmann-La Roche Ltd: Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLoren kalmBruno eschliSabine borngrRoche pharmaYvonne greenstreet mbchKirti pandeyTeresa grahamBirgit masjostGerard tobinNathalie altermattB circulation researchRoche group media relationsWorld health organizationRoche groupYvonne greenstreet